Background. In a number of investigations, hippocampal neurochemicals were evaluated in the patients with bipolar disorder who were on their first episode or euthymic periods. However, we did not meet any investigation in which only patients with bipolar depression were examined. As a consequence, the objective of the present study was to examine both sides of hippocampus of patients with bipolar disorder in depressive episode and healthy controls using 1H-MRS. Methods. Thirteen patients with DSM-IV bipolar I disorder, most recent episode depressed, were recruited from the Department of Psychiatry at Firat University School of Medicine. We also studied 13 healthy comparison subjects who were without any DSM-IV Axis I disorders recruited from the hospital staff. The patients and controls underwent proton magnetic resonance spectroscopy (1H-MRS) of their hippocampus. NAA, CHO, and CRE values were measured. Results. No significant effect of diagnosis was observed for NAA/CRE ratio. For the NAA/CHO ratio, the ANCOVA with age, gender, and whole brain volume as covariates revealed that the patients with bipolar depression had significantly lower ratio compared to healthy control subjects for right and for left side. As for the CHO/CRE ratio, the difference was statistically significant for right side, with an effect diagnosis of F = 4.763, P = 0.038, and was very nearly significant for left side, with an effect diagnosis of F = 3.732, P = 0.064. Conclusions. We found that the patients with bipolar depression had lower NAA/CHO and higher CHO/CRE ratios compared to those of healthy control subjects. The findings of the present study also suggest that there may be a degenerative process concerning the hippocampus morphology in the patients with bipolar depression. 1. Introduction Bipolar I disorder is a mood disorder according to Diagnostic and Statistical Manual of Mental Disorders Fourth Version (DSM-IV) characterized by at least one manic or mixed episode. Although the existence of depressive episodes is not required, these type of episodes frequently occurred in bipolar I disorder. Neurobiological factors have been implicated in the pathogenesis of bipolar I disorder, as in other psychiatric disorders. Recently, a huge number of neuroimaging investigations have been performed in patients with various psychiatric disorders to identify morphometric changes in specific brain areas. These techniques are noninvasive ones that provide our best understanding of the connection between the clinical features and related neurobiology in psychiatric disorders including
References
[1]
W. C. Drevets, J. L. Price, J. R. Simpson et al., “Subgenual prefrontal cortex abnormalities in mood disorders,” Nature, vol. 386, no. 6627, pp. 824–827, 1997.
[2]
Y. Hirayasu, M. E. Shenton, D. F. Salisbury et al., “Subgenual cingulate cortex volume in first-episode psychosis,” American Journal of Psychiatry, vol. 156, no. 7, pp. 1091–1093, 1999.
[3]
S. M. Strakowski, M. P. DelBello, K. W. Sax et al., “Brain magnetic resonance imaging of structural abnormalities in bipolar disorder,” Archives of General Psychiatry, vol. 56, no. 3, pp. 254–260, 1999.
[4]
L. L. Altshuler, G. Bartzokis, T. Grieder et al., “An MRI study of temporal lobe structures in men with bipolar disorder or schizophrenia,” Biological Psychiatry, vol. 48, no. 2, pp. 147–162, 2000.
[5]
P. Brambilla, K. Harenski, M. Nicoletti et al., “MRI investigation of temporal lobe structures in bipolar patients,” Journal of Psychiatric Research, vol. 37, no. 4, pp. 287–295, 2003.
[6]
A. L. Stoll, P. F. Renshaw, D. A. Yurgelun-Todd, and B. M. Cohen, “Neuroimaging in bipolar disorder: what have we learned?” Biological Psychiatry, vol. 48, no. 6, pp. 505–517, 2000.
[7]
K. Lyoo, H. K. Lee, J. H. Jung, G. G. Noam, and P. F. Renshaw, “White matter hyperintensities on magnetic resonance imaging of the brain in children with psychiatric disorders,” Comprehensive Psychiatry, vol. 43, no. 5, pp. 361–368, 2002.
[8]
M. Atmaca, H. Ozdemir, S. Cetinkaya et al., “Cingulate gyrus volumetry in drug free bipolar patients and patients treated with valproate or valproate and quetiapine,” Journal of Psychiatric Research, vol. 41, no. 10, pp. 821–827, 2007.
[9]
M. Atmaca, H. Ozdemir, and H. Yildirim, “Corpus callosum areas in first-episode patients with bipolar disorder,” Psychological Medicine, vol. 37, no. 5, pp. 699–704, 2007.
[10]
H. P. Blumberg, E. Stern, S. Ricketts et al., “Rostral and orbital prefrontal cortex dysfunction in the manic state of bipolar disorder,” American Journal of Psychiatry, vol. 156, no. 12, pp. 1986–1988, 1999.
[11]
M. Atmaca, H. Yildirim, H. Ozdemir, A. K. Poyraz, E. Tezcan, and E. Ogur, “Hippocampal 1H MRS in first-episode bipolar I patients,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 30, no. 7, pp. 1235–1239, 2006.
[12]
M. Atmaca, H. Yildirim, H. Ozdemir, E. Ogur, and E. Tezcan, “Hippocampal 1H MRS in patients with bipolar disorder taking valproate versus valproate plus quetiapine,” Psychological Medicine, vol. 37, no. 1, pp. 121–129, 2007.
[13]
J. Urenjak, S. R. Williams, D. G. Gadian, and M. Noble, “Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types,” Journal of Neuroscience, vol. 13, no. 3, pp. 981–989, 1993.
[14]
J. R. Moffett and M. A. A. Namboodiri, “Differential distribution of n-acetylaspartylglutamate and n-acetylaspartate immunoreactivities in rat forebrain,” Journal of Neurocytology, vol. 24, no. 6, pp. 409–433, 1995.
[15]
B. G. Jenkins, P. Klivenyi, E. Kustermann et al., “Nonlinear decrease over time in N-acetyl aspartate levels in the absence of neuronal loss and increases in glutamine and glucose in transgenic Huntington's disease mice,” Journal of Neurochemistry, vol. 74, no. 5, pp. 2108–2119, 2000.
[16]
O. A. C. Petroff, L. D. Errante, D. L. Rothman, J. H. Kim, and D. D. Spencer, “Neuronal and glial metabolite content of the epileptogenic human hippocampus,” Annals of Neurology, vol. 52, no. 5, pp. 635–642, 2002.
[17]
L. R. Baxter, J. M. Schwartz, M. E. Phelps et al., “Reduction of prefrontal cortex glucose metabolism common to three types of depression,” Archives of General Psychiatry, vol. 46, no. 3, pp. 243–250, 1989.
[18]
W. C. Drevets, “Prefrontal cortical-amygdalar metabolism in major depression,” Annals of the New York Academy of Sciences, vol. 877, pp. 614–637, 1999.
[19]
M. E. Winsberg, N. Sachs, D. L. Tate, E. Adalsteinsson, D. Spielman, and T. A. Ketter, “Decreased dorsolateral prefrontal N-acetyl aspartate in bipolar disorder,” Biological Psychiatry, vol. 47, no. 6, pp. 475–481, 2000.
[20]
H. Hamakawa, T. Kato, T. Shioiri, T. Inubushi, and N. Kato, “Quantitative proton magnetic resonance spectroscopy of the bilateral frontal lobes in patients with bipolar disorder,” Psychological Medicine, vol. 29, no. 3, pp. 639–644, 1999.
[21]
A. Bertolino, M. Frye, J. H. Callicott et al., “Neuronal pathology in the hippocampal area of patients with bipolar disorder: a study with proton magnetic resonance spectroscopic imaging,” Biological Psychiatry, vol. 53, no. 10, pp. 906–913, 2003.
[22]
K. Chang, N. Adleman, K. Dienes, N. Barnea-Goraly, A. Reiss, and T. Ketter, “Decreased N-Acetylaspartate in children with familial bipolar disorder,” Biological Psychiatry, vol. 53, no. 11, pp. 1059–1065, 2003.
[23]
J. C. Soares and J. J. Mann, “The functional neuroanatomy of mood disorders,” Journal of Psychiatric Research, vol. 31, no. 4, pp. 393–432, 1997.
[24]
G. Rajkowska, A. Halaris, and L. D. Selemon, “Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder,” Biological Psychiatry, vol. 49, no. 9, pp. 741–752, 2001.
[25]
G. J. Moore, J. M. Bebchuk, K. Hasanat et al., “Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2's neurotrophic effects?” Biological Psychiatry, vol. 48, no. 1, pp. 1–8, 2000.
[26]
R. F. Deicken, M. P. Pegues, S. Anzalone, R. Feiwell, and B. Soher, “Lower concentration of hippocampal N-acetylaspartate in familial bipolar I disorder,” American Journal of Psychiatry, vol. 160, no. 5, pp. 873–882, 2003.
[27]
A. Corapcioglu, O. Aydemir, M. Y？ld？z, et al., DSM-IV Eksen I Bozukluklar？ (SCID-I) ？？in Yap？land？r？lm？？ Klinik G？rü？me, Klinik Versiyon. Hekimler Yay？n Birli？i, Ankara, Turkey, 1999.
[28]
M. Hamilton, “A rating scale for depression,” Journal of Neurology, Neurosurgery, and Psychiatry, vol. 23, pp. 56–62, 1960.
[29]
R. C. Young, J. T. Biggs, V. E. Ziegler, and D. A. Meyer, “A rating scale for mania: reliability, validity and sensitivity,” British Journal of Psychiatry, vol. 133, no. 11, pp. 429–435, 1978.
[30]
J. Talairach and P. Tournoux, Coplanar Stereotaxic Atlas of the Human Brain, Thieme Medical Publishers, New York, NY, USA, 1998.
[31]
M. E. Winsberg, N. Sachs, D. L. Tate, E. Adalsteinsson, D. Spielman, and T. A. Ketter, “Decreased dorsolateral prefrontal N-acetyl aspartate in bipolar disorder,” Biological Psychiatry, vol. 47, no. 6, pp. 475–481, 2000.
[32]
M. Atmaca, H. Yildirim, H. Ozdemir, M. Koc, S. Ozler, and E. Tezcan, “Neurochemistry of the hippocampus in patients with obsessive-compulsive disorder: regular article,” Psychiatry and Clinical Neurosciences, vol. 63, no. 4, pp. 486–490, 2009.
[33]
I. M. Burtscher and S. Holtas, “Proton MR spectroscopy in clinical routine,” Journal of Magnetic Resonance Imaging, vol. 13, no. 4, pp. 560–567, 2001.
[34]
G. S. Malhi, M. Valenzuela, W. Wen, and P. Sachdev, “Magnetic resonance spectroscopy and its applications in psychiatry,” Australian and New Zealand Journal of Psychiatry, vol. 36, no. 1, pp. 31–43, 2002.
[35]
D. P. Soares and M. Law, “Magnetic resonance spectroscopy of the brain: review of metabolites and clinical applications,” Clinical Radiology, vol. 64, no. 1, pp. 12–21, 2009.
[36]
G. J. Moore and M. P. Galloway, “Magnetic resonance spectroscopy: neurochemistry and treatment effects in affective disorders,” Psychopharmacology Bulletin, vol. 36, no. 2, pp. 5–23, 2002.
[37]
A. Milne, G. M. MacQueen, K. Yucel, N. Soreni, and G. B. C. Hall, “Hippocampal metabolic abnormalities at first onset and with recurrent episodes of a major depressive disorder: a proton magnetic resonance spectroscopy study,” NeuroImage, vol. 47, no. 1, pp. 36–41, 2009.
[38]
H. Hortnagl, M. L. Berger, L. Havelec, and O. Hornykiewicz, “Role of glucocorticoids in the cholinergic degeneration in rat hippocampus induced by ethylcholine aziridinium (AF64A),” Journal of Neuroscience, vol. 13, no. 7, pp. 2939–2945, 1993.
